Table 5.
BA | ALK | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | ± | SD | 95% CI | Mean | ± | SD | 95% CI | |||||||
LAPre-EX | (mmol∙L−1) | Before | 1.07 | ± | 0.19 | 0.92 | - | 1.21 | 1.18 | ± | 0.27 | 0.97 | - | 1.39 |
After | 1.13 | ± | 0.26 | 0.93 | - | 1.33 | 1.10 | ± | 0.30 | 0.88 | - | 1.33 | ||
LAmax | (mmol∙L−1) | Before | 10.9 | ± | 1.6 | 9.7 | - | 12.1 | 10.9 | ± | 2.1 | 9.3 | - | 12.5 |
After | 10.2 | ± | 1.4 | 9.1 | - | 11.3 | 10.7 | ± | 1.9 | 9.2 | - | 12.2 | ||
LAR5 | (mmol∙L−1) | Before | 10.33 | ± | 1.64 | 9.07 | - | 11.59 | 9.99 | ± | 1.50 | 8.83 | - | 11.14 |
After | 9.57 | ± | 1.65 | 8.31 | - | 10.84 | 9.60 | ± | 1.55 | 8.41 | - | 10.79 | ||
LAR20 | (mmol∙L−1) | Before | 6.37 | ± | 1.77 | 5.01 | - | 7.73 | 6.27 | ± | 1.66 | 4.99 | - | 7.54 |
After | 5.80 | ± | 1.44 | 4.69 | - | 6.90 | 5.91 | ± | 1.60 | 4.68 | - | 7.14 | ||
LAR30 | (mmol∙L−1) | Before | 4.63 | ± | 1.58 | 3.42 | - | 5.85 | 4.21 | ± | 1.51 | 3.05 | - | 5.36 |
After | 4.13 | ± | 1.19 | 3.21 | - | 5.04 | 3.93 | ± | 1.33 | 2.91 | - | 4.96 | ||
NH3Pre-EX | (μmol∙L−1) | Before | 22.7 | ± | 1.9 | 21.2 | - | 24.1 | 22.6 | ± | 2.3 | 20.8 | - | 24.3 |
After | 20.8 | ± | 1.9* | 19.4 | - | 22.2 | 21.6 | ± | 2.4 | 19.7 | - | 23.4 | ||
NH3max | (μmol∙L−1) | Before | 80.3 | ± | 10.6 | 72.2 | - | 88.5 | 81.4 | ± | 8.7 | 74.8 | - | 88.1 |
After | 72.4 | ± | 10.2** | 64.6 | - | 80.3 | 74.2 | ± | 8.9 *** | 67.4 | - | 81.0 | ||
NH3R5 | (μmol∙L−1) | Before | 66.4 | ± | 15.9 | 54.2 | - | 78.7 | 69.2 | ± | 11.4 | 60.4 | - | 78.0 |
After | 61.1 | ± | 17.8 | 47.4 | - | 74.8 | 61.8 | ± | 8.7 | 55.1 | - | 68.5 | ||
NH3R20 | (μmol L−1) | Before | 48.2 | ± | 11.5 | 39.4 | - | 57.1 | 48.8 | ± | 6.8 | 43.6 | - | 54.0 |
After | 43.9 | ± | 12.4 | 34.3 | - | 53.4 | 44.4 | ± | 6.3 | 39.6 | - | 49.3 | ||
NH3R30 | (μmol∙L−1) | Before | 38.8 | ± | 6.5 | 33.8 | - | 43.8 | 37.8 | ± | 4.4 | 34.4 | - | 41.1 |
After | 34.8 | ± | 8.5 | 28.2 | - | 41.3 | 33.6 | ± | 4.6 | 30.0 | - | 37.1 | ||
WBCPre-EX | (x109∙L−1) | Before | 5.88 | ± | 1.32 | 4.86 | - | 6.89 | 5.76 | ± | 0.98 | 5.00 | - | 6.51 |
After | 5.27 | ± | 0.98 | 4.51 | - | 6.02 | 5.06 | ± | 0.80 | 4.44 | - | 5.67 | ||
LymPre-EX | (x109∙L−1) | Before | 1.74 | ± | 0.24 | 1.56 | - | 1.93 | 1.76 | ± | 0.36 | 1.48 | - | 2.03 |
After | 1.91 | ± | 0.19 | 1.77 | - | 2.06 | 1.86 | ± | 0.40 | 1.55 | - | 2.17 | ||
MonPre-EX | (x109∙L−1) | Before | 0.30 | ± | 0.10 | 0.22 | - | 0.38 | 0.41 | ± | 0.15 | 0.30 | - | 0.52 |
After | 0.38 | ± | 0.15 | 0.26 | - | 0.49 | 0.39 | ± | 0.13 | 0.29 | - | 0.49 | ||
GraPre-EX | (x109∙L−1) | Before | 3.81 | ± | 1.28 | 2.83 | - | 4.79 | 3.60 | ± | 0.79 | 2.99 | - | 4.21 |
After | 2.98 | ± | 0.82 | 2.35 | - | 3.60 | 2.81 | ± | 0.58 | 2.37 | - | 3.26 | ||
RBCPre-EX | (x1012∙L−1) | Before | 4.68 | ± | 0.50 | 4.29 | - | 5.06 | 4.96 | ± | 0.53 | 4.55 | - | 5.38 |
After | 4.60 | ± | 0.39 | 4.30 | - | 4.90 | 4.65 | ± | 0.38 | 4.36 | - | 4.95 | ||
HbPre-EX | (mmol∙L−1) | Before | 8.60 | ± | 0.86 | 7.94 | - | 9.27 | 8.78 | ± | 0.64 | 8.28 | - | 9.27 |
After | 8.47 | ± | 0.84 | 7.83 | - | 9.12 | 8.36 | ± | 0.43 | 8.03 | - | 8.69 | ||
HtPre-EX | (L∙L−1) | Before | 0.40 | ± | 0.04 | 0.37 | - | 0.43 | 0.41 | ± | 0.03 | 0.39 | - | 0.44 |
After | 0.40 | ± | 0.03 | 0.37 | - | 0.42 | 0.39 | ± | 0.02 | 0.38 | - | 0.41 |
Data are mean ± standard deviation (SD) and 95% confidence intervals (CI). *,**,***: significant difference between “Before” and “After” values (* p=0.006, ** p= 0.013, *** p=0.027). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; Gra granulocytes; Hb hemoglobin; Ht hematocrit; LA lactate; Lym lymphocytes; Mon monocytes; NH3 ammonia; Pre-EX pre-exercise values; R post-exercise recovery period (5, 20, 30 = minute of recovery); RBC red blood cells; TCM creatine malate; WBC white blood cells